Skip to main content
Inventage Lab Inc. logo

Inventage Lab Inc. — Investor Relations & Filings

Ticker · 389470 ISIN · KR7389470006 KO Professional, scientific and technical activities
Open in API
Filings indexed 195 across all filing types
Latest filing 2025-09-22 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 389470

About Inventage Lab Inc.

https://www.inventagelab.com/m/en/

Inventage Lab Inc. is a biopharmaceutical company specializing in the development of advanced Drug Delivery Systems (DDS). The company's foundation is its proprietary microfluidics-based platform technology, Laminar-FluiDigm™, which is applied to pharmaceutical research and manufacturing. Inventage Lab operates two primary platforms: IVL-DrugFluidic® for developing and producing microsphere-based long-acting injectables, and IVL-GeneFluidic® for the formulation and manufacturing of Lipid Nanoparticles (LNPs) for nucleic acid and gene therapies. The company's pipeline is focused on treating chronic and refractory diseases, with key programs targeting androgenic alopecia (male pattern baldness) and Alzheimer's disease. Other development areas include drug re-discovery for conditions like rheumatic arthritis and multiple sclerosis, and collaborative projects for HIV treatments and mRNA-based therapies.

Recent filings

Filing Released Lang Actions
전환청구권행사 (제2회차)
Share Issue/Capital Change Classification · 100% confidence The document is a formal notification regarding the exercise of conversion rights (전환청구권행사) for convertible bonds (전환사채) issued by Inventage Lab. It details the number of shares to be issued, the conversion price, and the remaining balance of the convertible bonds. This type of corporate action, involving the issuance of new shares resulting from debt conversion, falls under the category of capital changes or share issues.
2025-09-22 Korean
투자판단관련주요경영사항(임상시험결과) (알코올 의존성 및 opioid 의존성 치료제(IVL3004) 및 다발성 경화증 치료제(IVL4002) 제1상 임상시험 Topline 결과)
Legal Proceedings Report Classification · 100% confidence The document is a formal regulatory filing from a Korean company (Inventage Lab) submitted to the KRX (Korea Exchange). It details the 'Topline results' of a Phase 1 clinical trial. In the context of financial filings, announcements regarding clinical trial outcomes, regulatory approvals, or material business developments that do not fit into specific categories like earnings or dividends are classified as Regulatory Filings (RNS).
2025-09-10 Korean
반기보고서 (2025.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-Annual Report) for the company 'Inventage Lab' covering the period from January 1, 2025, to June 30, 2025. It contains detailed corporate information, financial data, and management disclosures required for a regulatory filing. As it is a comprehensive financial report for a period shorter than a full fiscal year, it falls under the 'Interim / Quarterly Report' category. H1 2025
2025-08-27 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a '임원ㆍ주요주주 특정증권등 소유상황보고서' (Report on Ownership of Specific Securities by Executives and Major Shareholders), which is a standard regulatory filing in South Korea (DART system) used to disclose insider transactions or changes in shareholdings by directors and major shareholders. This corresponds to the 'Director's Dealing' category.
2025-08-08 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed with the Korean Financial Supervisory Service. This document details the changes in share ownership by a specific executive (Park Dongseok) of Inventage Lab, including stock option exercises. This falls under the category of 'Director's Dealing' (DIRS), which covers personal share transactions by company directors and executives.
2025-08-08 Korean
투자판단관련주요경영사항 (FGF-21기반 mRNA-LNP 대사성 질환치료제 독점적 권리 도입 계약 체결)
M&A Activity Classification · 100% confidence The document is a regulatory filing from Inventage Lab regarding a 'Major Management Matter' (투자판단 관련 주요경영사항), specifically announcing the signing of an exclusive licensing and co-development agreement for a pharmaceutical product (FGF-21 based mRNA-LNP). This type of disclosure regarding business contracts, partnerships, and licensing deals is classified as a general regulatory filing (RNS) in the absence of a more specific category like M&A or capital raising.
2025-07-31 Korean

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.